Prismic has also secured Scarista’s exclusive license from Amarin Neuroscience to develop, market, and out-license patents covering highly purified forms of omega-3 fatty acids for the treatment of disorders of the central nervous system (CNS).
Prismic Pharmaceuticals Chairman and co-founder Peter Moriarty said following acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies to increase the commercial opportunity the patents offer in the CNS area.
"Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously," Moriarty added.
Prismic Pharmaceuticals is focused on the development and marketing of novel prescription pharmaceuticals for psychiatric and neurodegenerative disorders, and prescription medical foods for managing metabolic processes associated with CNS disorders.